BILLS-116hr6092ih.pdf
House Resolutions
0 pages
Page
of 0
Loading OCR text...
No OCR text available for this page.
Failed to load OCR text.
DATE (10)
2020
later than 90 days
MARCH 5, 2020
1996
later than 365 days
quarterly
6092 IH
yearly
annually
45-day
EVENT (2)
the ‘‘Veteran’s
SESSION
H. R. 6092
FAC (9)
PO 00000
Frm 00005
PO 00000
Frm 00006
PO 00000
Frm 00007
PO 00000
Frm 00009
PO 00000
Frm 00003
Fmt
PO 00000
Frm 00001
PO 00000
Frm 00004
PO 00000
Frm 00008
Fmt
PO 00000
Frm 00002
GPE (2)
6092 IH
the United States of America
ORG (38)
DSK79L0C42PROD
Department
Congress
Veterans Affairs
SEC
the Department of Veterans
the Food and Drug Administra-
Department medical
Medicare
the Centers for Disease Control
DEVELOPMENT OF NATIONAL CANCER OF THE
Senate
the Veterans Health Administration
Development of the Department of Veterans
Foundation
Medicaid Services
THE HOUSE OF REPRESENTATIVES
Veterans Health Administration
Academy of Sciences, Engineering
Research Institute
the National Institutes of Health
Institutes and Centers
RESEARCH OF PROSTATE CANCER
House of Representa-
Cancer Network
Department of Veterans Affairs
Cancer Treatment and Research Act
the Office of Research
Health and Health Disparities
the National Institute on Minor-
National Comprehensive
the Committee on Veterans’ Affairs
Prostate Cancer
Federal
the Department of Defense
National
the National Cancer Institute
PERSON (3)
kjohnson
CUNNINGHAM
DUNN
Topic Classifications
congressional legislation
95.3%
public health
64.2%
government oversight
50.3%
Extracted Keywords
prostate
prostate cancer
cancer
pathway
clinical
early detection
clinical trials
trials
veterans
comments
detection
high risk
early
veterans affairs
affairs establish
Forensic Analysis
PDF Metadata
- Creator
- ACOMP.exe WinVer 2.2a Sep 11 2014
- ModDate
- D:20221231210657Z
- Producer
- Acrobat Distiller 20.0 (Windows); modified using iText® Core 7.2.3 (production version) ©2000-2022 iText Group NV, Government Publishing Office
- CreationDate
- D:20200314021608-04'00'
Sentiment
Polarity
Neutral
0.099
Subjectivity
41%
Objective